Start here
It is not a scheduling fight.
The peptide debate keeps getting described as a "Schedule III" issue. It isn't. Scheduling belongs to the Controlled Substances Act, which governs drugs with abuse potential. Peptides are not in that conversation.
The actual fight is over FDA's compounding categories under Sections 503A and 503B of the Food, Drug, and Cosmetic Act — the rules that decide whether a licensed pharmacy may prepare a substance for a specific patient on a specific prescription. That is a narrower question than "is this legal," and it is the one that determines what a physician can actually put in a patient's hands.
The contradiction
What "FDA approved" does and does not mean.
A synthetic dye carries an affirmative federal listing. A physician working with a peptide through a licensed, inspected compounding pharmacy does not. That contradiction is exactly why this debate matters.
What actually happened
2026, in the order it occurred.
Health Secretary Robert F. Kennedy Jr. has publicly supported peptide access, arguing that restricting it through legitimate compounding pharmacies pushes demand into an unregulated gray market. In 2026, FDA reopened formal consideration of several peptides for the 503A pathway.
On July 23–24, 2026, FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides and recommended six for the 503A bulk drug substances list — BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon — over FDA staff arguments that the clinical evidence remains insufficient. It declined the seventh, emideltide (DSIP). Several of the votes were close.
Two things that are true at the same time
- A recommendation is not a rule. The committee is advisory. FDA still has to act through notice-and-comment rulemaking, and nothing has changed in law yet.
- 503A listing is not FDA approval. It would make a substance eligible for use in a compounded preparation pursuant to a prescription. It is not a finding that the drug is safe or effective for an indication, and it does not become one through this route.
We publish the rejection next to the recommendations deliberately. A committee that considered seven and declined one is a committee that was weighing evidence rather than clearing a category — and that is what makes the other six worth taking seriously. We maintain a live tracker of exactly where this stands.
The economics
The part nobody puts on the page.
Traditional drug approval is enormously expensive. For fiscal year 2026, the FDA application fee alone for a new drug application requiring clinical data is $4,682,003. That is the fee to have the application read — not the hundreds of millions that can go into developing and testing the drug it applies to.
That economic reality favors products that can eventually generate enough revenue to justify enormous development costs. It does not favor an inexpensive molecule that cannot be strongly patented or monetized. The absence of a large trial is often a statement about who could afford to run one — not about whether the compound does anything.
FDA's concerns are real and deserve serious evaluation: immunogenicity, impurities, and limited human safety data on several growth-hormone-related compounds, including ipamorelin. Those are the right questions to ask. But "we don't yet have billion-dollar pharmaceutical trials" should not automatically mean "licensed doctors and pharmacies may not use it." There should be another option.
Then collect the real-world data. Innovation in medicine rarely begins with certainty — it begins with a signal. Then clinicians study it, scientists test it, and the evidence evolves. Every requirement above is a mechanism for generating the very data the current argument says is missing.
Where Elevate Chicago stands
FDA should police quality, fraud and genuine safety risk. It should also create a workable pathway for physicians and regulated pharmacies to use emerging therapies responsibly — where the patient understands the uncertainty, the material is tested, and the outcome is monitored.
That is a materially harder position to dismiss than "the FDA should stay out of medicine," and it is the one we actually hold.
How that looks in practice. Every patient gets bloodwork and a clinical evaluation. Where a therapy is available to prescribe, we prescribe it and a licensed pharmacy fills it and ships it to you. Where it isn't, we tell you plainly what would have to change, where that process stands today, and we notify you when it moves. We do not sell research compounds to patients, and we do not send you elsewhere to buy them.
The question is not "FDA good" versus "FDA bad." It is this: how do we protect patients without allowing regulation to suffocate medical innovation, physician judgment and patient choice?